Renal Cell Carcinoma (RCC) — Deal Benchmarks & Valuation
Market Analysis
Renal Cell Carcinoma (RCC) is one of the most actively transacted indications in oncology licensing. Phase 2 deals for renal cell carcinoma (rcc) carry a median total deal value of $1.4B, with upfront payments ranging from $126M to $320M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Milestone structures for renal cell carcinoma (rcc) deals allocate $303M to development milestones, $485M to regulatory milestones, and $424M to commercial milestones. Royalty rates range from 11.3% to 18.6% at the base tier, with tiered escalation reaching 15.3%-22.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for renal cell carcinoma (rcc) licensing?
What royalty rates are standard for renal cell carcinoma (rcc) deals?
How are renal cell carcinoma (rcc) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.